Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores

@article{Lapchak2004CoadministrationON,
  title={Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores},
  author={Paul A. Lapchak and Donghuan Song and Jiandong Wei and Justin A. Zivin},
  journal={Experimental Neurology},
  year={2004},
  volume={188},
  pages={279-285}
}
Currently, the only FDA-approved treatment for acute ischemic stroke (AIS) is the thrombolytic, tissue plasminogen activator (tPA; alteplase; activase). It has been proposed that both the spin trap agent NXY-059 (cerovive) and tenecteplase (TNK-tPA), which are currently in phase II clinical trials, may also be useful for the treatment of ischemic stroke. However, there is little information available concerning the dose-response profiles or therapeutic window for NXY-059 in a validated embolic… Expand
Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model
TLDR
It is shown that reperfusion of ICA can increase RCBF following embolization, but this is not associated with improved neurological outcome measured using quantal analysis, and TNK administration significantly increased behavioral outcome when given 2 h following embolia; an increase that is not affected by combining TNK with REP. Expand
Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: Synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator
TLDR
The results suggest that simvastatin treatment may have clinical benefit when used alone or in the presence of tPA, but the therapeutic window using a single-dose regimen is narrow. Expand
Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development
  • P. Lapchak
  • Medicine
  • Translational Stroke Research
  • 2010
TLDR
The rabbit small clot embolic stroke model (RSCEM) remains the only preclinical model used to gain FDA approval of a therapeutic for stroke and can be used as an effective translational tool to gauge the clinical potential of new treatments. Expand
NXY-059: Review of Neuroprotective Potential for Acute Stroke
TLDR
Initial safety and efficacy data have not revealed any serious adverse events requiring special monitoring and/or precautions, with the exception of drug accumulation in patients with renal insufficiency. Expand
Is NXY-059 an advancement in the treatment of acute ischaemic stroke?
  • S. Doggrell
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2006
TLDR
The SAINT (Stoke Acute Ischemic N XY-059 Treatment) I trial has shown that, on the modified Rankin scale at 90 days, there were slightly more patients with no symptoms in the NXY-059 group than the placebo group, and Nxy-059 was well tolerated. Expand
Advances in ischemic stroke treatment: neuroprotective and combination therapies
TLDR
New thrombolytics are being developed with the goal of minimizing side effects, while also shortening the time of cerebral reperfusion and extending the therapeutic window of efficacy. Expand
The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: Synergism with tissue plasminogen activator
TLDR
The results show that the therapeutic window for a standard effective dose of tPA could be increased by administration of CGA, suggesting that it may be most useful as a co-therapy with a standard thrombolytic treatment regimen. Expand
The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: A combination therapy study with tissue plasminogen activator
TLDR
This study indicates that edaravone may have substantial therapeutic benefit for the treatment of AIS since it had a therapeutic widow of at least 3 h in rabbits. Expand
NXY-059: a hopeful sign in the treatment of stroke.
TLDR
The SAINT I trial represents the first “positive” neuroprotective trial in stroke and breaks a long string of “neuroprotective” failures and indicates some hope for stroke treatment. Expand
Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: A combination therapy study with tissue plasminogen activator
TLDR
It is suggested that TSC may be used for the treatment of AIS either alone or when administered before or concomitant with tPA to improve clinical rating scores with a therapeutic window for TSC therapy up to 3 h in rabbits. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits
TLDR
This study indicates that Tenecteplase has a wide therapeutic range, a therapeutic window of at least 3 h and a durable effect, and supports further investigation of TenectEplase in randomized double-blinded clinical trials in stroke patients. Expand
Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits
TLDR
The present study shows that microplasmin improves behavioral rating scores in the RSCEM when administered 60 minutes after embolization, at a dose that does not increase hemorrhages in theRLCEM, in contrast to tPA, which significantly enhances the hemorrhage rate inThe RLCEM. Expand
Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat
TLDR
This study demonstrates that intraarterial administration of TNK-tPA at 2 h of ischemia in the unanesthesthetized rat is effective in reducing neurological deficits and ischemic lesion volume without increasing hemorrhagic transformation and that administration ofTNK- tPA at 4 h ofIschemia does not increase the incidence of hemorrhagic Transformation. Expand
Ebselen, a Seleno-Organic Antioxidant, Is Neuroprotective After Embolic Strokes in Rabbits: Synergism With Low-Dose Tissue Plasminogen Activator
TLDR
This study indicates that ebselen may be neuroprotective when administered shortly after an embolic stroke, but the time- and dose-response analyses suggest that it has a narrow therapeutic window. Expand
Reducing Bleeding Complications After Thrombolytic Therapy for Stroke
TLDR
Preclinical studies indicate that MMP inhibition or free radical scavenging in combination with alteplase may circumvent the high risk of haemorrhaging with aleplase. Expand
Development of thrombolytic therapy for stroke: a perspective
  • P. Lapchak
  • Medicine
  • Expert opinion on investigational drugs
  • 2002
TLDR
Two important areas of drug discovery and development for the treatment of stroke include the development of novel plasminogen activators, such as recombinant desmodus rotundus salivary plasmineogen activator (rDSPA) alpha-1 (Schering/Teijin Pharmaceuticals) and a mutant fibrin-activated human plAsminogen (BB10153; British Biotech Inc.). Expand
Hyperacute stroke therapy with tissue plasminogen activator.
  • M. Alberts
  • Medicine
  • The American journal of cardiology
  • 1997
TLDR
Studies are under way to determine whether t-PA can be administered with an acceptable margin of safety within 5 hours of stroke, to evaluate the therapeutic benefits of intraarterial pro-urokinase, and to assess the use of magnetic resonance spectroscopy to identify which patients are most likely to benefit from thrombolysis. Expand
Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion.
TLDR
NXY-059 is an effective neuroprotective agent when administered 4 hours after pMCAO in a primate species, attenuating both motor and spatial neglect and substantially lessened the volume of cerebral damage. Expand
NXY-059, a Free Radical–Trapping Agent, Substantially Lessens the Functional Disability Resulting From Cerebral Ischemia in a Primate Species
TLDR
This novel drug has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species, and these findings provide considerable encouragement for the clinical development of NXY-059. Expand
Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke.
TLDR
The rationale for developing NXY-059 for the treatment of acute ischemic stroke is further supported by the drug's reported neuroprotective effects and may represent a useful adjunct stroke therapy to tPA, since preclinical studies have demonstrated that N XY-059 increases the therapeutic window for tPA and lowers the occurrence of tPA-induced ICH. Expand
...
1
2
3
4
...